Invion Ltd. engages in the development of treatments for respiratory and autoimmune disease. It develops the following drug assets: nadolol, zafirlukast, and ala-Cpn10. The company was founded on October 11, 2000 and is headquartered in Chermside, Australia.
|Market Price at 19-01-2018||$0.01|
|Price to Earnings Ratio||1.14|
|Market Capitalisation||$13.10 (million)|
|Return on Equity (ROE)||144.74%|